Author | Samuel A. Funt, MD

Articles

The Management of Advanced Germ Cell Tumors in 2016: The Memorial Sloan Kettering Approach

July 15, 2016

In this paper, we review the use of serum tumor markers in risk assignment and response evaluation; the treatment of previously untreated and relapsing patients; the role of surgical resection of residual disease, including retroperitoneal node dissection; and the importance of clinical trials for addressing unanswered questions and testing new therapies.

CTLA-4 Antibodies: New Directions, New Combinations

November 11, 2014

This review will summarize the preclinical and clinical development of CTLA-4–blocking antibodies, discuss recent insights into the biology of CTLA-4 blockade, review the use of these antibodies in combination with established and novel therapeutic modalities, and comment on ongoing questions regarding their administration.